Nuclear Medicine: Page 102

Eckert & Ziegler posts 9-month financial results

By AuntMinnie.com staff writers

Isotope technology firm Eckert & Ziegler has posted financial results for the nine-month period ending 30 September.

November 3, 2016

JNM: Florbetaben-PET detects cardiac amyloidosis

By Wayne Forrest

Australian researchers have shown the proficiency of PET with the radiotracer F-18 florbetaben to detect abnormal deposits of proteins in the heart in a study published in the November issue of the Journal of Nuclear Medicine.

November 3, 2016

Navidea posts Q3 revenue increases

By AuntMinnie.com staff writers

Radiopharmaceutical developer Navidea Biopharmaceuticals posted revenue increases and lower net losses in the third quarter of 2016, part of which it attributed to sales growth of its Lymphoseek radiopharmaceutical and a milestone payment from Cardinal Health.

November 2, 2016

Gamma Medica brings MBI to Henry Ford

By AuntMinnie.com staff writers

Molecular imaging developer Gamma Medica has taken an order for its LumaGem molecular breast imaging (MBI) system from Henry Ford Health System in Detroit.

November 2, 2016

Novel PET compound could aid Alzheimer's detection

By Wayne Forrest

Researchers at Washington University School of Medicine in St. Louis have developed a chemical compound that detects amyloid deposits on PET scans better than currently approved imaging agents, according to a paper published November 2 in Scientific Reports.

November 2, 2016

Lantheus posts flat Q3 results despite US contrast growth

By AuntMinnie.com staff writers

Strong U.S. sales of its Definity ultrasound contrast agent and stable revenues from U.S. nuclear products helped Lantheus Holdings offset international doldrums in the company's third-quarter financial report.

November 1, 2016

DMS again drives Digirad results higher

By AuntMinnie.com staff writers

Nuclear medicine firm Digirad saw sharp growth in revenue for its third quarter thanks to the addition of sales from its acquisition of DMS Health in January 2016. The company posted a net loss for the period, however.

October 31, 2016

Jubilant Pharma taps new DraxImage president

By AuntMinnie.com staff writers

Jubilant Pharma, parent company of radiopharmaceutical developer Jubilant DraxImage, has appointed a new president to the subsidiary, Michael Rossi. His post is effective immediately.

October 26, 2016

Second Opinion: Did thyroid imaging study miss the mark?

By Dr. Mark Tulchinsky

In an article published July 21 in BMJ, researchers from the University of Michigan Comprehensive Cancer Center questioned whether the use of imaging after treatment for thyroid cancer improved patient outcomes. Dr. Mark Tulchinsky of Pennsylvania State University offers a response in this Second Opinion column.

October 26, 2016

Nuclear med, radiopharmaceutical market primed for growth

By AuntMinnie.com staff writers

The global market for nuclear medicine equipment and radiopharmaceuticals generated $4.7 billion in revenues in 2016 and is expected to grow at a compound annual growth rate of 9.3% to reach $7.3 billion by 2021, according to a new report from MarketsandMarkets.

October 24, 2016

Blue Earth PET radiotracer IDs prostate cancer recurrence

By AuntMinnie.com staff writers

Radiopharmaceutical developer Blue Earth Diagnostics is highlighting results from a phase III clinical trial of its Axumin (fluciclovine F-18) PET radiopharmaceutical agent indicating a 68% detection rate for prostate cancer recurrence.

October 23, 2016

CMR Naviscan highlights PEM study

By AuntMinnie.com staff writers

PET developer Compañía Mexicana de Radiología (CMR) Naviscan is highlighting clinical results regarding positron emission mammography (PEM) published September 2 in European Radiology.

October 20, 2016

Previous Page

Page 102 of 438

Next Page